WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317635
CAS#: 120014-06-4 (free base)
Description: Donepezil is a medication used in the palliative treatment of Alzheimer's disease. Donepezil is used to improve cognition and behavior of people with Alzheimer's, but does not slow the progression of or cure the disease.
Hodoodo Cat#: H317635
Name: Donepezil
CAS#: 120014-06-4 (free base)
Chemical Formula: C24H29NO3
Exact Mass: 379.21
Molecular Weight: 379.492
Elemental Analysis: C, 75.96; H, 7.70; N, 3.69; O, 12.65
Related CAS #: 120014-06-4 (free base) 120011-70-3 (HCl) 142698-19-9 (R-isomer) 142057-80-5 (S-isomer)
Synonym: HSDB 7743; HSDB7743; HSDB-7743; Donepezil
IUPAC/Chemical Name: 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one
InChi Key: ADEBPBSSDYVVLD-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
SMILES Code: O=C1C(CC2CCN(CC3=CC=CC=C3)CC2)CC4=C1C=C(OC)C(OC)=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 379.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, Dash A. Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. CNS Neurosci Ther. 2016 Mar;22(3):159-66. doi: 10.1111/cns.12484. Epub 2016 Jan 18. Review. PubMed PMID: 26778658.
2: Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Prog Neurobiol. 2016 Jan 18. pii: S0301-0082(15)00162-8. doi: 10.1016/j.pneurobio.2015.12.003. [Epub ahead of print] Review. PubMed PMID: 26797191.
3: Szigeti K, Hafeez MU. Exploring the role of donepezil in dementia with Lewy bodies. Drugs Today (Barc). 2015 Oct;51(10):579-90. doi: 10.1358/dot.2015.51.10.2389166. Review. PubMed PMID: 26583300.
4: Lee JH, Jeong SK, Kim BC, Park KW, Dash A. Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance. Acta Neurol Scand. 2015 May;131(5):259-67. doi: 10.1111/ane.12386. Epub 2015 Feb 18. Review. PubMed PMID: 25690270.
5: Lane RM, Darreh-Shori T. Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value. J Alzheimers Dis. 2015;44(4):1039-62. doi: 10.3233/JAD-142268. Review. PubMed PMID: 25408210.
6: de Medeiros K, Basting A. "Shall I compare thee to a dose of donepezil?": cultural arts interventions in dementia care research. Gerontologist. 2014 Jun;54(3):344-53. doi: 10.1093/geront/gnt055. Epub 2013 Jun 7. Review. PubMed PMID: 23749388.
7: Prvulovic D, Schneider B. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease. Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):1039-50. doi: 10.1517/17425255.2014.915028. Epub 2014 Apr 30. Review. PubMed PMID: 24785550.
8: Rodrigues Simões MC, Dias Viegas FP, Moreira MS, de Freitas Silva M, Riquiel MM, da Rosa PM, Castelli MR, dos Santos MH, Soares MG, Viegas C Jr. Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease. Mini Rev Med Chem. 2014 Jan;14(1):2-19. Review. PubMed PMID: 24251806.
9: Ikeda K, Yanagihashi M, Sawada M, Hanashiro S, Kawabe K, Iwasaki Y. Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors. Intern Med. 2014;53(9):1007-10. Epub 2014 May 1. Review. PubMed PMID: 24785894.
10: Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690. Review. PubMed PMID: 24662102.
11: Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013 May;19(5):294-301. doi: 10.1111/cns.12076. Epub 2013 Mar 6. Review. PubMed PMID: 23462265.
12: Toda N. [Nitrergic cerebrovascular regulation as affected by donepezil]. Nihon Yakurigaku Zasshi. 2013 Mar;141(3):150-4. Review. Japanese. PubMed PMID: 23470480.
13: Molino I, Colucci L, Fasanaro AM, Traini E, Amenta F. Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials. ScientificWorldJournal. 2013 Oct 29;2013:925702. doi: 10.1155/2013/925702. eCollection 2013. Review. PubMed PMID: 24288512; PubMed Central PMCID: PMC3830825.
14: Cheewakriengkrai L, Gauthier S. A 10-year perspective on donepezil. Expert Opin Pharmacother. 2013 Feb;14(3):331-8. doi: 10.1517/14656566.2013.760543. Epub 2013 Jan 14. Review. PubMed PMID: 23316713.
15: Thakurathi N, Vincenzi B, Henderson DC. Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia. Expert Opin Investig Drugs. 2013 Feb;22(2):259-65. doi: 10.1517/13543784.2013.750650. Epub 2012 Dec 9. Review. PubMed PMID: 23215841.
16: Damulin IV. [Donepezil in Alzheimer's disease and vascular dementia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7):71-5. Review. Russian. PubMed PMID: 24073452.
17: Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J Alzheimers Dis. 2013;35(2):349-61. doi: 10.3233/JAD-122140. Review. PubMed PMID: 23411693.
18: Constantinescu MI, Constantinescu DP, Andercou A, Mironiuc IA. Influence of sildenafil and donepezil administration on the serum redox balance in experimentally induced lower limb critical ischemia. Clujul Med. 2013;86(3):250-8. Epub 2013 Aug 5. Review. PubMed PMID: 26527957; PubMed Central PMCID: PMC4462506.
19: Christensen DD. Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease. Postgrad Med. 2012 Nov;124(6):110-6. doi: 10.3810/pgm.2012.11.2589. Review. PubMed PMID: 23322144.
20: Doody RS, Cummings JL, Farlow MR. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Curr Alzheimer Res. 2012 Sep;9(7):773-81. Review. PubMed PMID: 22175653.
